Eric Fung has been promoted by Ciphergen to the position of vice president, clinical and medical affairs, in its new diagnostics division. Fung will manage clinical and medical research underlying the company’s clinical diagnostics business initiative in the area of protein molecular diagnostics.
Fung, who was most recently director of clinical affairs at Ciphergen, joined the company in 2000 as a lead scientist in its Biomarker Discovery Center laboratories, where he managed Ciphergen’s Collaborations with academic and pharmaceutical companies. Before joining Ciphergen, he was a Howard Hughes sponsored researcher at Stanford University, in Richard Scheller’s lab. Fung received his MD and PhD degree in molecular neuroscience from Johns Hopkins University School of Medicine, and has a BS in biology from California Institute of Technology. He is also currently an Adjunct Assistant Professor in the Department of Pathology at Johns Hopkins University School of Medicine.
Leslie Browne has been appointed president and chief executive officer of Pharmacopeia Drug Discovery. Browne has most recently been chief operating officer of Iconix Pharmaceuticals, which does chemogenomics, and chief operating officer of GeneTrace, a functional genomics company. Between 1990 to 2000 he held senior positions at Berlex/ Schering AG, and before that, held positions at Ciba Geigy. Browne received his PhD from the University of Michigan and was an NIH Postdoctoral Fellow at Harvard with Nobel laureate R.B. Woodward.
James Meer has been appointed vice president, chief financial officer, secretary, and treasurer of Pharmos. Prior to joining Pharmos, Meer was a strategic consultant to specialty pharmaceutical and biotech firms. Meer served eight years as vice president and treasurer of Schein Pharmaceutical where he was responsible for capital formation, including a successful IPO, strategic planning and investor relations. He has also held positions at EnviroSource, John Labatt, and General Host Corporation. Meer holds an MBA from Pace University and a BA in Economics from Rutgers College.
Ken Welsh has been appointed to the scientific advisory board of Health Discovery Corporation, a biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets. Welsh is currently a professor of clinical genomics at Royal Brompton Hospital and Imperial College in London. He is also a science advisor to the West London Transplant Center, and a visiting professor at Oxford University and the University of Utrecht. He received his Bsc, PhD, and DSc from Newcastle University.
Health Discovery Corporation also has named Vladimir Vapnik to its scientific advisory board. Vapnik, who won the Humboldt Research award in 2003, is currently a senior researcher at NEC Research. He has worked for AT&T Bell Laboratories and AT&T Labs-Research.
Alamo Pharmaceuticals has appointed Paul Duffy executive vice president. Duffy comes to the Beverly Hills, Calif., pharmaceutical CRO and marketing firm from Novartis, where he managed the marketing and sales of Clozaril (clozapine.) as the head of the neuroscience sales group.